Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oleg Lipatov

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 17, 2018
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 studyAna M Molina, Thomas E Hutson, Dmitry Nosov, et al.
Future Oncology (London, England)|March 30, 2016
Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancerNadia Harbeck, Oleg Lipatov, Mona Frolova, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 8, 2022
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind StudyRubi K Li, Eriko Tokunaga, Hryhoriy Adamchuk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancerLuca Gianni, Gilles H Romieu, Michail Lichinitser, et al.
NPJ Breast Cancer|October 2, 2025
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapyJavier Cortes, Oleg Lipatov, Seock-Ah Im, et al.
The Lancet. Oncology|September 22, 2014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialHansjochen Wilke, Kei Muro, Eric Van Cutsem, et al.
The Lancet. Oncology|March 7, 2021
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trialEric P Winer, Oleg Lipatov, Seock-Ah Im, et al.
The New England Journal of Medicine|July 20, 2022
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast CancerJavier Cortes, Hope S Rugo, David W Cescon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancerJohn R Mackey, Manuel Ramos-Vazquez, Oleg Lipatov, et al.
Lancet (London, England)|December 6, 2020
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortes, David W Cescon, Hope S Rugo, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
European Journal of Cancer (Oxford, England : 1990)|March 17, 2018
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 studyAna M Molina, Thomas E Hutson, Dmitry Nosov, et al.
Future Oncology (London, England)|March 30, 2016
Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancerNadia Harbeck, Oleg Lipatov, Mona Frolova, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 8, 2022
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind StudyRubi K Li, Eriko Tokunaga, Hryhoriy Adamchuk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancerLuca Gianni, Gilles H Romieu, Michail Lichinitser, et al.
NPJ Breast Cancer|October 2, 2025
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapyJavier Cortes, Oleg Lipatov, Seock-Ah Im, et al.
The Lancet. Oncology|September 22, 2014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialHansjochen Wilke, Kei Muro, Eric Van Cutsem, et al.
The Lancet. Oncology|March 7, 2021
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trialEric P Winer, Oleg Lipatov, Seock-Ah Im, et al.
The New England Journal of Medicine|July 20, 2022
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast CancerJavier Cortes, Hope S Rugo, David W Cescon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancerJohn R Mackey, Manuel Ramos-Vazquez, Oleg Lipatov, et al.
Lancet (London, England)|December 6, 2020
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortes, David W Cescon, Hope S Rugo, et al.
Pageof 2